2015 was a truly eventful year for Biocartis. It was marked by many transitions, which some see as a prelude to the company becoming a globally active market leader. Biocartis saw the source of its income shift from R&D to sales, as it was the first full financial year since the launch of its diagnostic platform Idylla™. In April 2015, the diagnostics producer delivered a stellar IPO, with the demand for Biocartis shares exceeding the availability by 6.5 times. 2016 is already off to a strong start: After recent collaboration deals with industry greats such as Merck and Amgen, Biocartis seems to be well on its way to becoming a force in the diagnostics market.
Plenty of good news for ADx NeuroSciences. Today, the Ghent-based Alzheimer specialist has announced the end of its third capital round as well as a new agreement with their American partner Quanterix. Both the capital raise and the new deal are milestones for ADx and will fuel the company’s growth in the coming years.
2015 was a truly eventful year for Biocartis. It was marked by many transitions, which some see as a prelude to the company becoming a globally active market leader. Biocartis saw the source of its income shift from R&D to sales, as it was the first full financial year since the launch of its diagnostic platform Idylla™. In April 2015, the diagnostics producer delivered a stellar IPO, with the demand for Biocartis shares exceeding the availability by 6.5 times. 2016 is already off to a strong start: After recent collaboration deals with industry greats such as Merck and Amgen, Biocartis seems to be well on its way to becoming a force in the diagnostics market.
Plenty of good news for ADx NeuroSciences. Today, the Ghent-based Alzheimer specialist has announced the end of its third capital round as well as a new agreement with their American partner Quanterix. Both the capital raise and the new deal are milestones for ADx and will fuel the company’s growth in the coming years.